Meds and you

27 September 2013

Clobetasol

Clobetasol is a topical corticosteroid. They reduce inflammation and are effective for treating inflammatory skin conditions.

0

Clobetasol is the active ingredient of Clobex shampoo (Nappi code: 710464-001), Dermovate cream (Nappi code: 718718-003), Dermovate scalp application (Nappi code: 824216-008), Dermovate ointment (Nappi code: 718726-006), Dovate cream (Nappi code: 807249-009), Dovate ointment (Nappi code: 807230-006), Xenovate cream (Nappi code: 868299-006) and Xenovate ointment (Nappi code: 868302-007).

General information

Clobetasol is a topical corticosteroid. Topical corticosteroids are drugs that that are formulated for use on the skin. They reduce inflammation and are effective for treating inflammatory skin conditions.

In South Africa clobetasol is registered for the treatment of psoriasis; eczema; steroid responsive dermatosis, and scalp psoriasis.

Clobetasol is considered to be one of the strongest topical corticosteroids available and should therefore only be used in the treatment of conditions that did not respond to other topical steroids.

This medication should be applied sparingly and as a thin layer to the affected area of the skin. Do not apply to broken skin, or apply more of the medication than directed. Misuse of this medicine may lead to thinning of the skin, or when systemically absorbed, a decrease in the production of natural hormones by the adrenal glands.

Speak to your doctor before applying this medicine to infected skin.

How does clobetasol work?

When applied to the skin, clobetasol reduces the release of inflammatory chemicals. This reduces inflammation and its associated symptoms.

Fast facts

Drug schedule: schedule 4

Available as: slobetasol is available as cream, ointment, scalp application and shampoo.

What does it do? Clobetasol relieves inflammation of the skin.

Overdose risk: low

Dependence risk: low

Is clobetasol available as a generic? yes

Is clobetasol available on prescription only? yes

User information

Onset of effect: within 12 hours

Duration of action: up to 24 hours

Stopping this medicine: do not stop using this medication abruptly as it may cause a recurrence of the original symptoms being treated. Consult your doctor prior to discontinuing treatment.

Prolonged use: this medicine is generally not used for longer than 4 weeks.

Special precautions

Consult your doctor before using this drug if:

  • you have a bacterial, fungal or viral skin infection
  • you have porphyria
  • you have skin ulcers
  • you have acne, or rosacea

Pregnancy: avoid. It is unknown how this medication may affect your baby. Consult your doctor before using this drug, or if you are planning to fall pregnant.

Breastfeeding: avoid. It is unknown how this medication may affect your baby. Consult your doctor before use.

Porphyria: avoid. This medication may cause serious adverse effects. Consult your doctor before use.

Infants and children: this medication is not intended for use in children under the age of 1 year. Shampoo only for use in adults.

The elderly: no special precautions need to be taken.

Driving and hazardous work: no special precautions need to be taken.

Alcohol: no special precautions need to be taken.

Possible side effects

Side effects Frequency
Consult your doctor

Common Rare Only if severe In all cases
skin irritation x
x
skin thinning
x
x
strech marks
x x
weight gain
x
x
hypertension
x
x
mood changes
x
x

Interactions

Drug interactions

Interactions are uncommon when this medication is used as directed

Overdose action

A small overdose is no cause for concern. In case of intentional large overdose, seek emergency medical attention.

Recommended dosage

Apply sparingly to the affected area 1 - 2 times daily.

______________________________________________________________________________

This material is not intended to substitute medical advice, but is for informational purposes only.

Please consult a physician for specific treatment and recommendations.

 
 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.